http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2042488-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2004-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce9cc8d28ef9809024728104e5b895d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7a3afe5c4b8bdef727a2e12cfbafe53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afbf9251aa58445d3b0c75ea0afe743f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86064d1bd14f87527398d0b2bd8b3744 |
| publicationDate | 2009-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2042488-A1 |
| titleOfInvention | Matrix metalloproteinase inhibitors |
| abstract | Compounds of Formula (I):n nWherein: A represents bond, C 1-6 alkyl or CH=CH-C 1-4 alkyl; nB represents bond, O, S, SO, SO 2 , CO, CR 7 R 8 , CO 2 R 14 , CONR 14 R 15 , N(COR 14 )(COR 15 ), N(SO 2 R 14 )(COR 15 ) or NR 14 R 15 ; nD represents bond, or C 1-6 alkyl; nE represents substituted aryl or substituted or unsubstituted heteroaryl; nQ represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; nX represents O, S, SO, SO 2 , CO, CNR 5 , CNOR 5 , CNNR 5 R 6 , NR 11 or CR 7 R 8 ; nY represents CR 5 OR 11 , CR 5 SR 11 , NOR 5 , CR 5 NR 6 R 11 , SO, SO 2 , CO, CNR 5 , CNOR 5 or CS; nR 1 and R 1' each independently represents H, C 1-6 alkyl or C 1-4 alkylaryl; nR 2 represents CO 2 R 12 , CH 2 OR 12 or CONR 12 R 13 , CONR 12 OR 13 , NR 12 COR 13 , SR 12 , PO(OH) 2 , PONHR 12 or SONHR 12 ; nR 3 represents H, C 1-6 alkyl or C 1-4 alkylaryl; nR 4 represents optionally substituted aryl or heteroaryl; nZ represents a bond, CH 2 , O, S, SO, SO 2 , NR 5 , OCR 5 R 6 , CR 9 R 10 O or Z, R 4 and Q together form an optionally substituted fused tricyclic group; nR 5 and R 6 each independently represent H, C 1-6 alkyl or C 1-4 alkylaryl; nR 7 and R 8 each independently represent H, halo, C 1-6 alkyl or C 1-4 alkylaryl; nR 9 and R 10 each independently represents H, C 1-6 alkyl optionally substituted by halo, cyano, OR 11 or NR 6 R 11 , C 1-4 alkylaryl optionally substituted by halo, cyano, OR11 or NR 6 R 11 , OR 11 or, together with the N to which they are attached, R 9 and R 10 form a heterocyclic group: nR 11 represents H, C 1-6 alkyl, C 1-4 alkylaryl or COR 5 ; nR 12 and R 13 each independently represent H, C 1-3 alkyl, C 1-3 alkylaryl or C 1-3 alkylheteroaryl or, together with the functionality to which they are attached, R 12 and R 13 form a heterocyclic group: nR 14 and R 15 each independently represent H, C 1-6 alkyl, C 1-4 alkylaryl or C 1-4 alkylheteroaryl or together with the functionality to which they are attached R 14 and R 15 form a heterocyclic or fused heterocyclic group: and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described. |
| priorityDate | 2003-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.